Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-058809
Filing Date
2025-04-25
Accepted
2025-04-25 16:40:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A janx_defa14a_2025_non_xb.htm DEFA14A 25525
2 GRAPHIC img188147199_0.jpg GRAPHIC 558319
3 GRAPHIC img188147199_1.jpg GRAPHIC 67140
  Complete submission text file 0000950170-25-058809.txt   887571
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40475 | Film No.: 25874805
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)